Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Pharmacol Res. 2020 Dec 28;164:105374. doi: 10.1016/j.phrs.2020.105374

Table 2.

Representative colorectal cancer clinical trials utilizing dendritic cell vaccines

Clinicaltrials.gov identifier (Estimated completion year) Phase CRC indication Treatment
NCT01885702 (2020) I/II Adjuvant DC vaccine for MSI-positive CRC/preventative DC vaccine for germline MMR-gene mutation carriers Autologous DC vaccine loaded with CEA, and frameshift-derived neoantigens
NCT02503150 (2020) III Metastatic CRC with no previous therapy for metastatic lesions Autologous DC vaccine loaded with autologous tumor lysate in combination with modified FOLFOX-6
NCT03152565 (2020) I/II MSS metastatic CRC treated with at least two forms of chemotherapy Autologous DC vaccine in combination with avelumab
NCT03730948 (2021) I Surgically resected stage I and II hypermutated CRC Autologous DC vaccine with mutated peptides
NCT02919644 (2024) II Curative resection of stage IV CRC Autologous DC vaccine with autologous tumor lysate followed by IL-2 injection

Abbreviations used: carcinoembryonic antigen (CEA), colorectal cancer (CRC), dendritic cell (DC), mismatch repair (MMR), microsatellite instability (MSI), microsatellite stable (MSS)